Poging GOUD - Vrij

When is the ‘right’ time to quit your job?

Mint Hyderabad

|

October 13, 2025

If you leave a job too early, you risk looking impatient. On the other hand, staying too long can lead to stagnation, burnout or resentment

- Geetika Sachdev

When is the ‘right’ time to quit your job?

By Thursday afternoon, Rohit Sharma already knew how his Friday would end. The content lead at a Mumbai-based advertising agency would be on back-to-back calls, clearing last-minute escalations, and logging off exhausted well past 9pm. The weekend offered little respite. By Sunday evening, the familiar heaviness returned. “I stopped recognizing myself,” the 38-year-old says. “I was snappy with my team, perpetually tired, and constantly thinking about quitting. But I was also scared of what would happen if I did.”

Across the country in Bengaluru, Ananya Nair faced a different dilemma. For the 34-year-old brand manager at a global FMCG company, everything was “right” on paper: a good salary, a swanky office, and international work trips. Yet, she felt hollow. She recalls, “I would sit in meetings wondering why I was even there. The only time I felt alive was on weekends, cooking and filming recipes for Instagram.

Two professionals, two very different jobs. Both confronting the same question: Had their roles run their course?

The decision to quit is one of the hardest career decisions to make. If you leave too early, you risk looking impatient. On the other hand, staying too long can lead to stagnation, burnout, or resentment.

For most, the decision to quit doesn’t arise from a single bad day. It’s the result of a slow accumulation of fatigue, frustration, and disconnection. Overwork is often the first sign.

Sharma recalls waking up each morning dreading the day ahead; not because of one impossible boss or multiple deadlines, but because the rhythm of his work had become unsustainable. “I wasn’t performing badly,” he says, “but I was permanently exhausted.”

MEER VERHALEN VAN Mint Hyderabad

Mint Hyderabad

Mint Hyderabad

Nvidia, Eli Lilly to invest $1 bn in AI lab

Nvidia Corp. plans to invest $1 billion over five years in a new laboratory with Eli Lilly & Co., aiming to speed up the use of artificial intelligence (AI) in the pharmaceutical industry.

time to read

1 min

January 13, 2026

Mint Hyderabad

Shadowfax IPO to open next week

Logistics services provider Shadowfax is set to launch its ₹1,900-crore initial public offering (IPO) next week, targeting a valuation of ₹7,400 crore, people familiar with the matter said on Monday.

time to read

1 min

January 13, 2026

Mint Hyderabad

The US climate cop-out should galvanize others

America's withdrawal from the global battle against climate change is a signal for the rest of the world to unite for the greater good. The cause is vital, not the participation of the US

time to read

2 mins

January 13, 2026

Mint Hyderabad

Toyota pushes for fuel norm clarity

The government should soon come out with the final notification for the next phase of India’s Corporate Average Fuel Efficiency standards so that the industry can prepare accordingly, according to a senior Toyota Kirloskar Motor executive.

time to read

1 min

January 13, 2026

Mint Hyderabad

Food effect lifts Dec CPI inflation

India's retail inflation rose for the second successive month in December, data released by the statistics ministry on Monday showed, driven by a moderation in negative food inflation and an uptick in core inflation.

time to read

1 min

January 13, 2026

Mint Hyderabad

Mint Hyderabad

Commissions trump advice in wealth management biz

surge on rising affluence, strong economic growth, higher foreign direct investments, and the growth of the startup ecosystem.

time to read

2 mins

January 13, 2026

Mint Hyderabad

The Chinese company taking on the world's memory-chip giants

As AI demand drives prices up, CXMT beats Washington's curbs to vie with Micron and South Korean leaders

time to read

4 mins

January 13, 2026

Mint Hyderabad

HC lifts ban on Zydus cancer biosimilar till patent expiry

In a relief for Zydus Lifesciences, a division bench of the Delhi High Court on Monday allowed the drugmaker to sell and market its biosimilar of the anticancer drug nivolumab in India, citing public interest.

time to read

2 mins

January 13, 2026

Mint Hyderabad

Fix GST on capital goods to revive private investment

India faces a paradox today.

time to read

3 mins

January 13, 2026

Mint Hyderabad

Mint Hyderabad

Feeling tired? It could be too many messages

The cumulative stress of constant notifications is leaving many emotionally burnt out. Tackling it requires small, sustainable changes

time to read

4 mins

January 13, 2026

Listen

Translate

Share

-
+

Change font size